MRNA Stock Price and Chart — BCBA:MRNA

Key facts today

Moderna's updated COVID-19 vaccine for the SARS-CoV-2 LP.8.1 variant was approved by Health Canada on August 21, 2025, and is under review by other global regulators.

Moderna affirmed the safety and effectiveness of its vaccines at a recent ACIP meeting, countering claims about mRNA's long-term presence in the body with data from controlled studies.

Moderna has delivered its first made-in-Canada mRNA vaccines to multiple Canadian provinces and territories.

Analyze the impact Analyze the impact

About Moderna, Inc.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Check out other big names from the same industry as MRNA.